A Plausible Candidate Turning Off The

Total Page:16

File Type:pdf, Size:1020Kb

A Plausible Candidate Turning Off The RESEARCH HIGHLIGHTS IN THE NEWS METASTASIS Stress is good for you? Women who experience increased levels of stress A plausible candidate are less likely to develop breast cancer, according to a study by Danish Cancer mortality is most often the suppressor gene Brms1. However, GTPase activating protein (GAP) scientists (Nielsen, N. R. et result of metastasis rather than this gene has no obvious polymor- that negatively regulates RAP1 and al., Br. Med. J. 9 September the primary tumour. Previous phisms that influence metastasis RAP2 GTPases. Human SIPA1 has 2005 (doi: 10.1136/ studies from Kent Hunter’s group and so was discounted from this recently been found to interact bmj.38547.638183.06)). demonstrated that the genetic study. with the water channel aquaporin 2 Stress can reduce oestrogen production and background of the host can influ- To identify other potential can- (AQP2), by its PDZ domain, so the oestrogen is a known risk ence metastatic efficiency. Now, didates the authors used a multiple authors used AQP2 to see if the factor in breast cancer. Hunter and colleagues have identi- cross-mapping strategy that uses alanine to threonine substitution Therefore, the authors fied a candidate gene, Sipa1, with the shared haplotypes in different affected this interaction. They followed the incidence of an amino-acid polymorphism that inbred strains of mice to reduce the found that it did — the FVB allele breast cancer in the 6,689 influences this process. number of candidate genes. This bound AQP2 less effectively. women of the Copenhagen The authors previously used a reduced the number of potential What does this mean biologi- City Heart Study who had assessed their own stress mouse model of breast cancer to genes from 500 to 23, which were cally? Transient transfection assays levels between 1981 and investigate the effect of constitu- then prioritized based on their demonstrated that the FVB allele is 1983. They found that 251 tional genetic polymorphism on known molecular function. After less efficient than the DBA allele at women developed breast metastasis. They expressed the analysing and discounting several reducing the activity of GTP RAP1. cancer, and that those who polyoma middle-T transgene in of the genes, the authors found that AQP2 inhibits this and does so more had put themselves in the various strains of inbred mice and Sipa1 had a polymorphism that effectively with the DBA allele. So, higher stress category were 40% less at risk. through quantitative trait genetic results in an alanine (as found in cells expressing the FVB allele will However, caution has been mapping showed the presence of a the DBA mouse strain) to threonine have reduced levels of Rap–GTP advised from all quarters. putative metastasis efficiency locus (as found in the FVB mouse strain) activity. Reducing the expression “Even though we find a lower (Mtes1) on mouse chromosome 19. substitution in a protein–protein of Sipa1 in cells in vitro indicates risk of breast cancer among This chromosome region, which is interaction domain known as a that SIPA1 modulates the adhesive stressed women, let me orthologous to human 11q12–13, PDZ domain. Sipa1 is a mitogen- properties of cells, consistent with just emphasize that stress cannot be considered a harbours a known metastasis inducible gene that encodes a its effect on RAP1, which is known healthy response”, said lead researcher Naja Rod Nielsen of the National Institute of SIGNALLING The mitogen-activated protein Public Health in Copenhagen kinase (MAPK) signalling pathway (http://www.forbes.com, activates many important cell 9 September 2005). Previously, stress had Turning off the tap processes, such as proliferation, been thought to increase but how are these signals ever the risk of breast cancer. turned off? Madhu Macrae et Emma Pennery from Breast al. report that downstream gene Cancer Care, UK, said targets of the pathway, such as the “We know from talking to gene encoding the ephrin receptor women with breast cancer A2 (EPHA2), mediate a negative that some of them believe feedback loop that is lost in cancer stress to be a contributory cells. factor. This new study is therefore very interesting” In a search for MAPK pathway (http://news.bbc.co.uk, gene targets, Macrae et al. 9 September 2005). observed that expression of the Summing up, Sarah receptor tyrosine kinase EPHA2 Rawlings, of Breakthrough was upregulated fivefold when Breast Cancer, UK, MAPK signalling was activated. reminded people that Interestingly, they also found that “…maintaining a healthy, once EPHA2 is transported to the balanced lifestyle is cell surface, it binds to its ligand, important — we know that ephrin-A1, and MAPK signalling high stress levels can lead to unhealthy behaviour, is downregulated. This seems to which may alter your risk be a negative feedback loop that of breast cancer and other controls MAPK signalling and diseases” (http://www. cell proliferation. guardian.co.uk, Previous studies had shown 9 September 2005). that the EPHA2 receptor tyrosine Patrick Goymer 754 | OCTOBER 2005 | VOLUME 5 www.nature.com/reviews/cancer © 2005 Nature Publishing Group RESEARCH HIGHLIGHTS of Sipa1 decreased the numbers of IN BRIEF pulmonary metastases from a highly metastatic mammary tumour cell line. Conversely, overexpression VACCINES of the FVB allele increased the T cell-mediated suppression of angiogenesis results in numbers of pulmonary metastases. tumor protective immunity. Analysis of human tumours also demonstrated that overexpression of Zhou, H. et al. Blood 106, 2026–2032 (2005) SIPA1 is associated with metastatic Tumour growth can be inhibited by anti-angiogenic progression. intervention. The authors had previously shown that These results demonstrate that vaccination with a complete copy of the murine growth factor Sipa1, as determined by its overall receptor gene Flk1 triggered the production of antibodies protein concentration and/or its against proliferating endothelial cells in the tumour vasculature. availability to inactivate RAP1, Now they show that the use of an engineered minigene modulates metastatic progression. containing only one cytotoxic epitope of Flk1, delivered to The data also predict that homo- mice in a Salmonella-based vector, results in an antibody that zygotes for the DBA allele would prevents angiogenesis and protects against various tumours, but have reduced metastatic capacity does not cross react with healthy tissue. because, in the primary tumour, cells are more likely to closely inter- CANCER GENETICS act with one another. Additional Dido gene expression alterations are implicated in the studies are required to verify this induction of hematological myeloid neoplasms. and to investigate another potential gene close to Sipa1 that might also Fütterer, A. et al. J. Clin. Invest. 115, 2351–2362 (2005) contribute to the Mtes1 locus. Myelodysplastic/myeloproliferative diseases (MDS/MPDs) are a Nicola McCarthy heterogeneous group of myeloid neoplasms that are associated with deletions on chromosome 20q. The authors map the to affect cell–cell interactions. But References and links death inducer-obliterator (DIDO) gene to this location and does Sipa1 influence metastasis? ORIGINAL RESEARCH PAPER Park, Y. G. et al. show that all patients with MDS/MPDs have DIDO-expression Sipa1 is a candidate for the metastasis efficiency A series of experiments in mouse modifier locus Mtes1. Nature Genet. 4 September abnormalities. Furthermore, targeting Dido in mice caused a models showed that RNA inhibition 2005 (doi: 10.1038/ng1635) disease with symptoms similar to those of MDS/MPDs. These results indicate that DIDO might be a tumour suppressor gene for MDS/MPDs. kinase is commonly overexpressed receptor on adjoining cell types TUMORIGENESIS in human cancers, including keeps cell proliferation in check. 40% of breast cancers. So, how When this structure is lost, such Genetic ablation of cyclin D1 abrogates genesis of rhabdoid can cancer cells express high as during tumour formation, tumors resulting from Ini1 loss levels of EPHA2 and maintain EPHA2-expressing cells no Tsikitis, M. et al. Proc. Natl Acad. Sci. USA 102, 12129–12134 (2005) signalling along the MAPK longer interact with ephrin-A1 pathway? A survey of EPHA2 produced by neighbouring cells, Rhabdoid tumours are aggressive paediatric malignancies and its ligand in a panel of 28 resulting in uncontrolled MAPK that arise because of the loss of the tumour suppressor gene breast cancer cell lines revealed signalling and proliferation. INI1. INI1 represses cyclin D1 (CCND1) gene expression, and that cells that overexpress In support of this model, the authors found that Ini1+/–mice develop rhabdoid tumours EPHA2 do not express ephrin- the authors showed that that have defective INI1 expression but express CCND1. A1 — expression of the receptor ERBB transformation, which CCND1 de-repression is therefore important for rhabdoid and its ligand is mutually is mediated by the MAPK tumorigenesis. exclusive. This is because in signalling pathway, is suppressed addition to upregulating the by ephrin-A1 expression in TELOMERES expression of EPH2A, another cultured cells. The authors outcome of MAPK signalling is suggest that maintaining normal XPF nuclease-dependent telomere loss and increased downregulation of the ephrin-A1 interactions between ephrin DNA damage in mice overexpressing TRF2 result in gene EFNA1. ligands and receptors is an premature aging and cancer. The authors propose that in important mechanism of tissue Muñoz, P. et al. Nature Genet. 4 September 2005 (doi: 10.1038/ng1633) normal tissue architecture, one homeostasis that is disrupted cell type downregulates MAPK during the development of breast TRF2, a protein that functions to protect telomeric ends of signalling and is therefore able and other cancers. DNA, paradoxically induces increased rates of skin cancer to express ephrin-A1, whereas Kristine Novak when overexpressed in mouse skin. The authors show that neighbouring cells activate the References and links TRF2 interacts with the ultraviolet light-induced DNA repair MAPK signalling pathway and ORIGINAL RESEARCH PAPER Macrae, M. nuclease XPF and activates XPF function at telomeres.
Recommended publications
  • Single Nucleotide Variants in Metastasis-Related Genes Are
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE HHS Public Access provided by CDC Stacks Author manuscript Author ManuscriptAuthor Manuscript Author Mol Carcinog Manuscript Author . Author manuscript; Manuscript Author available in PMC 2018 March 01. Published in final edited form as: Mol Carcinog. 2017 March ; 56(3): 1000–1009. doi:10.1002/mc.22565. Single nucleotide variants in metastasis-related genes are associated with breast cancer risk, by lymph node involvement and estrogen receptor status, in women with European and African ancestry Michelle R. Roberts1,2,3, Lara E. Sucheston-Campbell4, Gary R. Zirpoli5, Michael Higgins6, Jo L. Freudenheim3, Elisa V. Bandera7, Christine B. Ambrosone2, and Song Yao2 1Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 2Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 3Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY 4Division of Pharmacy Practice and Science, The Ohio State University, Columbus, OH 5Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 6Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY 7Rutgers Cancer Institute of New Jersey, New Brunswick, NJ Abstract Background—Single nucleotide polymorphisms (SNPs) in pathways influencing lymph node (LN) metastasis and estrogen receptor (ER) status in breast cancer may partially explain inter- patient variability in prognosis. We examined 154 SNPs in 12 metastasis-related genes for associations with breast cancer risk, stratified by LN and ER status, in European-American (EA) and African-American (AA) women. Methods—2,671 women enrolled in the Women’s Circle of Health Study were genotyped.
    [Show full text]
  • Review Article Multiple Endocrine Neoplasia Type 2 And
    J Med Genet 2000;37:817–827 817 J Med Genet: first published as 10.1136/jmg.37.11.817 on 1 November 2000. Downloaded from Review article Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis Jordan R Hansford, Lois M Mulligan Abstract diseases for families. Elucidation of genetic Multiple endocrine neoplasia type 2 (MEN mechanisms and their functional consequences 2) is an inherited cancer syndrome char- has also given us clues as to the broader acterised by medullary thyroid carcinoma systems disrupted in these syndromes which, in (MTC), with or without phaeochromocy- turn, have further implications for normal toma and hyperparathyroidism. MEN 2 is developmental or survival processes. The unusual among cancer syndromes as it is inherited cancer syndrome multiple endocrine caused by activation of a cellular onco- neoplasia type 2 (MEN 2) and its causative gene, RET. Germline mutations in the gene, RET, are a useful paradigm for both the gene encoding the RET receptor tyrosine impact of genetic characterisation on disease kinase are found in the vast majority of management and also for the much broader MEN 2 patients and somatic RET muta- developmental implications of these genetic tions are found in a subset of sporadic events. MTC. Further, there are strong associa- tions of RET mutation genotype and disease phenotype in MEN 2 which have The RET receptor tyrosine kinase led to predictions of tissue specific re- MEN 2 arises as a result of activating mutations of the RET (REarranged during quirements and sensitivities to RET activ- 1–5 ity. Our ability to identify genetically, with Transfection) proto-oncogene.
    [Show full text]
  • SIPA1 Is a Modulator of HGF/MET Induced Tumour Metastasis Via the Regulation of Tight Junction-Based Cell to Cell Barrier Function
    cancers Article SIPA1 Is a Modulator of HGF/MET Induced Tumour Metastasis via the Regulation of Tight Junction-Based Cell to Cell Barrier Function Chang Liu 1, Wenguo Jiang 1 , Lijian Zhang 2, Rachel Hargest 1,* and Tracey A. Martin 1,* 1 Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; [email protected] (C.L.); [email protected] (W.J.) 2 Peking University School of Oncology and Peking University Cancer Hospital, Fucheng Road, Beijing 100142, China; [email protected] * Correspondence: [email protected] (R.H.); [email protected] (T.A.M.); Tel.: +44-29-2068-7130 (R.H.) Simple Summary: The role of Signal Induced Proliferation Associated 1 (SIPA1) in lung cancer remains largely unknown. This study aimed to evaluate the importance of SIPA1 in the development and progression of lung cancer, to demonstrate the cellular functions of SIPA1 and the molecular mechanisms involved. Abstract: Background: Lung cancer is the leading cause of cancer death. SIPA1 is a mitogen induced GTPase activating protein (GAP) and may hamper cell cycle progression. SIPA1 has been shown to be involved in MET signaling and may contribute to tight junction (TJ) function and cancer metastasis. Methods: Human lung tumour cohorts were analyzed. In vitro cell function assays were performed after knock down of SIPA1 in lung cancer cells with/without treatment. Quantitative Citation: Liu, C.; Jiang, W.G.; Zhang, polymerase chain reaction (qPCR) and western blotting were performed to analyze expression of L.; Hargest, R.; Martin, T.A. SIPA1 Is a HGF (hepatocyte growth factor), MET, and their downstream markers.
    [Show full text]
  • A Genome-Wide Library of MADM Mice for Single-Cell Genetic Mosaic Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.05.136192; this version posted June 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Contreras et al., A Genome-wide Library of MADM Mice for Single-Cell Genetic Mosaic Analysis Ximena Contreras1, Amarbayasgalan Davaatseren1, Nicole Amberg1, Andi H. Hansen1, Johanna Sonntag1, Lill Andersen2, Tina Bernthaler2, Anna Heger1, Randy Johnson3, Lindsay A. Schwarz4,5, Liqun Luo4, Thomas Rülicke2 & Simon Hippenmeyer1,6,# 1 Institute of Science and Technology Austria, Am Campus 1, 3400 Klosterneuburg, Austria 2 Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria 3 Department of Biochemistry and Molecular Biology, University of Texas, Houston, TX 77030, USA 4 HHMI and Department of Biology, Stanford University, Stanford, CA 94305, USA 5 Present address: St. Jude Children’s Research Hospital, Memphis, TN 38105, USA 6 Lead contact #Correspondence and requests for materials should be addressed to S.H. ([email protected]) 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.06.05.136192; this version posted June 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Contreras et al., SUMMARY Mosaic Analysis with Double Markers (MADM) offers a unique approach to visualize and concomitantly manipulate genetically-defined cells in mice with single-cell resolution.
    [Show full text]
  • The Erbb Receptor Tyrosine Family As Signal Integrators
    Endocrine-Related Cancer (2001) 8 151–159 The ErbB receptor tyrosine family as signal integrators N E Hynes, K Horsch, M A Olayioye and A Badache Friedrich Miescher Institute, PO Box 2543, CH-4002 Basel, Switzerland (Requests for offprints should be addressed to N E Hynes, Friedrich Miescher Institute, R-1066.206, Maulbeerstrasse 66, CH-4058 Basel, Switzerland. Email: [email protected]) (M A Olayioye is now at The Walter and Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Victoria 3050, Australia) Abstract ErbB receptor tyrosine kinases (RTKs) and their ligands have important roles in normal development and in human cancer. Among the ErbB receptors only ErbB2 has no direct ligand; however, ErbB2 acts as a co-receptor for the other family members, promoting high affinity ligand binding and enhancement of ligand-induced biological responses. These characteristics demonstrate the central role of ErbB2 in the receptor family, which likely explains why it is involved in the development of many human malignancies, including breast cancer. ErbB RTKs also function as signal integrators, cross-regulating different classes of membrane receptors including receptors of the cytokine family. Cross-regulation of ErbB RTKs and cytokines receptors represents another mechanism for controlling and enhancing tumor cell proliferation. Endocrine-Related Cancer (2001) 8 151–159 Introduction The EGF-related peptide growth factors The epidermal growth factor (EGF) or ErbB family of type ErbB receptors are activated by ligands, known as the I receptor tyrosine kinases (RTKs) has four members:EGF EGF-related peptide growth factors (reviewed in Peles & receptor, also termed ErbB1/HER1, ErbB2/Neu/HER2, Yarden 1993, Riese & Stern 1998).
    [Show full text]
  • Unveiling the Molecular Mechanisms Regulating the Activation of the Erbb Family Receptors at Atomic Resolution Through Molecular Modeling and Simulations
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Spring 2011 Unveiling the Molecular Mechanisms Regulating the Activation of the ErbB Family Receptors at Atomic Resolution through Molecular Modeling and Simulations Andrew Shih University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Biophysics Commons, Other Biomedical Engineering and Bioengineering Commons, and the Structural Biology Commons Recommended Citation Shih, Andrew, "Unveiling the Molecular Mechanisms Regulating the Activation of the ErbB Family Receptors at Atomic Resolution through Molecular Modeling and Simulations" (2011). Publicly Accessible Penn Dissertations. 302. https://repository.upenn.edu/edissertations/302 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/302 For more information, please contact [email protected]. Unveiling the Molecular Mechanisms Regulating the Activation of the ErbB Family Receptors at Atomic Resolution through Molecular Modeling and Simulations Abstract The EGFR/ErbB/HER family of kinases contains four homologous receptor tyrosine kinases that are important regulatory elements in key signaling pathways. To elucidate the atomistic mechanisms of dimerization-dependent activation in the ErbB family, we have performed molecular dynamics simulations of the intracellular kinase domains of the four members of the ErbB family (those with known kinase activity), namely EGFR, ErbB2 (HER2)
    [Show full text]
  • Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics
    Oncogene (2007) 26, 6577–6592 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Targeting the function of the HER2 oncogene in human cancer therapeutics MM Moasser Department of Medicine, Comprehensive Cancer Center, University of California, San Francisco, CA, USA The year 2007 marks exactly two decades since human HER3 (erbB3) and HER4 (erbB4). The importance of epidermal growth factor receptor-2 (HER2) was func- HER2 in cancer was realized in the early 1980s when a tionally implicated in the pathogenesis of human breast mutationally activated form of its rodent homolog neu cancer (Slamon et al., 1987). This finding established the was identified in a search for oncogenes in a carcinogen- HER2 oncogene hypothesis for the development of some induced rat tumorigenesis model(Shih et al., 1981). Its human cancers. An abundance of experimental evidence human homologue, HER2 was simultaneously cloned compiled over the past two decades now solidly supports and found to be amplified in a breast cancer cell line the HER2 oncogene hypothesis. A direct consequence (King et al., 1985). The relevance of HER2 to human of this hypothesis was the promise that inhibitors of cancer was established when it was discovered that oncogenic HER2 would be highly effective treatments for approximately 25–30% of breast cancers have amplifi- HER2-driven cancers. This treatment hypothesis has led cation and overexpression of HER2 and these cancers to the development and widespread use of anti-HER2 have worse biologic behavior and prognosis (Slamon antibodies (trastuzumab) in clinical management resulting et al., 1989).
    [Show full text]
  • Crosstalk Between EGFR and Trkb Enhances Ovarian Cancer Cell Migration and Proliferation
    1003-1011 9/9/06 14:04 Page 1003 INTERNATIONAL JOURNAL OF ONCOLOGY 29: 1003-1011, 2006 Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation LIHUA QIU1,2, CHANGLIN ZHOU1, YUN SUN1,2, WEN DI1, ERICA SCHEFFLER2, SARAH HEALEY2, NICOLA KOUTTAB3, WENMING CHU4 and YINSHENG WAN2 1Department of OB/GYN, Renji Hospital, Shanghai Jiaotong University, Shanghai 200001, P.R. China; 2Department of Biology, Providence College, Providence, RI 02918; 3Department of Pathology, Roger Williams Medical Center, Boston University, Providence, RI 02908; 4Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02903, USA Received March 16, 2006; Accepted May 17, 2006 Abstract. Ovarian cancer remains the leading cause of fatality combination of inhibitors of both receptors with cell survival among all gynecologic cancers, although promising therapies pathway inhibitors would provide a better outcome in the are in the making. It has been speculated that metastasis is clinical treatment of ovarian cancer. critical for ovarian cancer, and yet the molecular mechanisms of metastasis in ovarian cancer are poorly understood. Growth Introduction factors have been proven to play important roles in cell migration associated with metastasis, and inhibition of growth Ovarian cancer is the most frequent cause of cancer death factor receptors and their distinct cell signaling pathways has among all gynecologic cancers, and therapies over the last 30 been intensively studied, and yet the uncovered interaction or
    [Show full text]
  • Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer Running Title
    Author Manuscript Published OnlineFirst on January 20, 2017; DOI: 10.1158/0008-5472.CAN-16-1921 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Uvyr)Thvp ru v rpr hv h r hpvhrq vu rhhv v vh py rphy phpr Svt vyr) 6u ) " #$ % & '$ $( $)*# $ ,$$ - ./ 0 1 " , $'2 / ' - , $$03$, 4, 5$ $ 6 7$ % & 8 8$ 9 6ssvyvhv) . 8 : .2 $ 5 1 $ ; $ ;# < %. 8 : ., , $ ;# $ < -: . $, 8 $ . . 8 ; $ ;# /. 8 : . $; $ ;# < 0= $ 1 2 . , >2,, $ ?&, $ 2 . & $ , $@ ABA%B, $ < 4: . $ $ $ ; $ ;# < 6: .2 $ 5 1 $ .@ $ $ $ = $ ; $ ;# < Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on January 20, 2017; DOI: 10.1158/0008-5472.CAN-16-1921 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. & 8 * $$ < 9& $8 C 8 < 8$ D< < 8syvp s vr rC & . $@ $, $ ', $E $ . $ 8$:7'@ < % Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on January 20, 2017; DOI: 10.1158/0008-5472.CAN-16-1921 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 6i hpC& 8 . . $ $ >? $ <& . # $# . $ $ .464A6 22)2 . $. E<& # $ >?. $ . ). $ . ) . $$ 222 2 < $ $ . @ . <& 8$. $ ., ::)$$@,. ) $ ),@$$<F .8 222 . , $) ,::)$$ ), $E <& 8# # $8 , < - Downloaded from cancerres.aacrjournals.org on September 26, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on January 20, 2017; DOI: 10.1158/0008-5472.CAN-16-1921 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. D qpv #$ .$$) $ .. 8 >&5?>?<& . 8@ #$ $#$ # $ 8$ .8 .
    [Show full text]
  • Activation of Transmembrane Cell-Surface Receptors Via a Common Mechanism? the ‘‘Rotation Model’’
    Insights & Perspectives Hypotheses Activation of transmembrane cell-surface receptors via a common mechanism? The ‘‘rotation model’’ Ichiro N. Maruyama It has long been thought that transmembrane cell-surface receptors, such as typically consist of an extracellular receptor tyrosine kinases and cytokine receptors, among others, are activated by domain (ECD) and an intracellular ligand binding through ligand-induced dimerization of the receptors. However, domain (ICD) separated by a single transmembrane domain (TMD), with there is growing evidence that prior to ligand binding, various transmembrane the exception of bacterial receptors receptors have a preformed, yet inactive, dimeric structure on the cell surface. such as the aspartate receptor (Tar) Various studies also demonstrate that during transmembrane signaling, ligand and the serine receptor (Tsr), which binding to the extracellular domain of receptor dimers induces a rotation of have another TMD at their amino transmembrane domains, followed by rearrangement and/or activation of termini. Ligand binding to their ECDs often regulates kinases that are either intracellular domains. The paper here describes transmembrane cell-surface integrated into the receptor ICD, or receptors that are known or proposed to exist in dimeric form prior toligand binding, physically associated with the ICD. and discusses how these preformed dimers are activated by ligand binding. Apart from receptors that initiate signaling pathways inside cells via Keywords: tyrosine phosphorylation, there are .cytokine; dimerization; ligand binding; preformed dimer; transmembrane receptors in bacteria, fungi, and plants signaling; tyrosine kinase that phosphorylate histidine residues upon ligand binding. Furthermore, natriuretic peptide receptors, which are receptor-type guanylyl cyclases, Introduction cell membranes to the cytoplasm, and produce cGMP upon peptide binding.
    [Show full text]
  • Polymorphic Genetic Control of Tumor Invasion in a Mouse Model of Pancreatic Neuroendocrine Carcinogenesis
    Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis Matthew G. H. Chuna,b,c,d, Jian-Hua Maoc,1, Christopher W. Chiub,c, Allan Balmainc, and Douglas Hanahana,b,c,2,3 aDepartment of Biochemistry and Biophysics, bDiabetes Center, and cHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143; and dProgram in Biological Sciences, University of California, San Francisco, CA 94158 Contributed by Douglas Hanahan, August 31, 2010 (sent for review August 2, 2010) Cancer is a disease subject to both genetic and environmental hallmark capability for invasive growth in the RT2 mouse model influences. In this study, we used the RIP1-Tag2 (RT2) mouse of cancer. model of islet cell carcinogenesis to identify a genetic locus that influences tumor progression to an invasive growth state. RT2 Results mice inbred into the C57BL/6 (B6) background develop both non- PNET Progression to Invasive Carcinoma Is Modulated by Genetic invasive pancreatic neuroendocrine tumors (PNET) and invasive Background. Following anecdotal observations that PNETs de- carcinomas with varying degrees of aggressiveness. In contrast, veloping in RT2 mice inbred into the C3H background were RT2 mice inbred into the C3HeB/Fe (C3H) background are compar- predominantly noninvasive, we carefully examined the distribu- atively resistant to the development of invasive tumors, as are RT2 tion of the distinctive invasive phenotypes in de novo PNETs C3HB6(F1) hybrid mice. Using linkage analysis, we identified a 13- arising in RT2 mice inbred into either the B6 or C3H genetic Mb locus on mouse chromosome 17 with significant linkage to the backgrounds, as well as in C3HB6(F1) hybrids (F1), to determine development of highly invasive PNETs.
    [Show full text]
  • Extracellular Juxtamembrane Motif Critical for Trkb Preformed Dimer and Activation
    cells Article Extracellular Juxtamembrane Motif Critical for TrkB Preformed Dimer and Activation Jianying Shen 1,2, Dang Sun 1, Jingyu Shao 1, Yanbo Chen 1, Keliang Pang 1, Wei Guo 1,3 and Bai Lu 1,3,* 1 School of Pharmaceutical Sciences, IDG/McGovern Institute for Brain Research, Tsinghua University, Beijing 100084, China 2 Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100084, China 3 R & D Center for the Diagnosis and Treatment of Major Brain Diseases, Research Institute of Tsinghua University in Shenzhen, Shenzhen 518057, China * Correspondence: [email protected]; Tel.: +86-10-6278-5101 Received: 29 May 2019; Accepted: 15 August 2019; Published: 19 August 2019 Abstract: Receptor tyrosine kinases are believed to be activated through ligand-induced dimerization. We now demonstrate that in cultured neurons, a substantial amount of endogenous TrkB, the receptor for brain-derived neurotrophic factor (BDNF), exists as an inactive preformed dimer, and the application of BDNF activates the pre-existing dimer. Deletion of the extracellular juxtamembrane motif (EJM) of TrkB increased the amount of preformed dimer, suggesting an inhibitory role of EJM on dimer formation. Further, binding of an agonistic antibody (MM12) specific to human TrkB-EJM activated the full-length TrkB and unexpectedly also truncated TrkB lacking ECD (TrkBdelECD365), suggesting that TrkB is activated by attenuating the inhibitory effect of EJM through MM12 binding-induced conformational changes. Finally, in cells co-expressing rat and human TrkB, MM12 could only activate TrkB human-human dimer but not TrkB human-rat TrkB dimer, indicating that MM12 binding to two TrkB monomers is required for activation.
    [Show full text]